title: An unexpected trismus.
authors.affiliation: Medical Intensive Care Unit, Hospital Saint-Antoine, Paris, France. mikael.alves@sat.aphp.fr
authors.forename: Mikael
authors.initials: M
authors.lastname: Alves
authors.forename: Etienne
authors.initials: E
authors.lastname: Canoui
authors.forename: Lionel
authors.initials: L
authors.lastname: Deforges
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.forename: Bertrand
authors.initials: B
authors.lastname: Guidet
authors.forename: Georges
authors.initials: G
authors.lastname: Offenstadt
authors.forename: Eric
authors.initials: E
authors.lastname: Maury
mesh_terms: D000058:Accidental Falls; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000276:immunology*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000276:immunology*; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000009:adverse effects / Q000276:immunology; D012307:Risk Factors; D000069283:Rituximab; D013742:Tetanus / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000628:therapy; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014313:Trismus / Q000209:etiology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D013745:Tetanus Toxoid; D000069283:Rituximab; D003520:Cyclophosphamide; D011241:Prednisone